Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | EED | O75530 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.66 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.66 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.66 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767365 | 1.00 | EZH2 (0.81) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797381 | 0.97 | EZH2 (0.79) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797383 | 0.95 | EZH2 (0.73) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797365 | 0.95 | EZH2 (0.75) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797391 | 0.95 | EZH2 (0.75) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797378 | 0.95 | EZH2 (0.74) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797385 | 0.95 | EZH2 (0.72) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797370 | 0.94 | EZH2 (0.71) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797377 | 0.92 | EZH2 (0.69) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17797389 | 0.92 | EZH2 (0.68) | EZH2NR1I2EEDABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3220916-B1 | METHOD FOR TREATING CANCER WITH N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL) AMINO)-4-METHYL-4'-(MORPHOLINOMETHYL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE | EPIZYME INC (US) | 2023-04-19 | — | — | EP | claimed |
| US-20170360797-A1 | METHOD FOR TREATING CANCER | Epizyme, Inc. | 2017-12-21 | — | — | US | claimed |
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4272742-A1 | EPZ-6438 FOR USE IN A METHOD FOR TREATING CANCER | Epizyme Inc (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3220916-B1 | METHOD FOR TREATING CANCER WITH N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL) AMINO)-4-METHYL-4'-(MORPHOLINOMETHYL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE | EPIZYME INC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4140487-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme Inc (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220315566-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2022-10-06 | — | — | US | disclosed |
| US-11370781-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-2836216-B1 | COMBINATION THERAPY FOR TREATING CANCER | EPIZYME INC (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-110191722-B | Pharmaceutical composition for treating HTLV-1 related myelopathy | 第一三共株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-20190100514-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-10155002-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180318309-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2018-11-08 | — | — | US | disclosed |
| US-9855275-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170305890-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2017-10-26 | — | — | US | disclosed |
| US-20170305889-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2017-10-26 | — | — | US | disclosed |
| US-20170252349-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2017-09-07 | — | — | US | disclosed |
| US-20170119780-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2017-05-04 | — | — | US | disclosed |
| EP-2697199-B1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100514-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885NR1I2 2699/4885EED 16/4885 |
| US-11370781-B2 | Combination therapy for treating cancer | EZH2, BMI1, HDAC2 | EZH2 1/4885NR1I2 2153/4885EED 14/4885 |
| US-20170360797-A1 | METHOD FOR TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885NR1I2 2467/4885EED 26/4885 |
| US-20170252349-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-20170305889-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885NR1I2 2699/4885EED 16/4885 |
| US-20170305890-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885NR1I2 2699/4885EED 16/4885 |
| US-20220315566-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885NR1I2 2699/4885EED 16/4885 |
| US-10155002-B2 | Aryl- or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-20170119780-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-20180318309-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.